CL2023000412A1 - Derivados cíclicos de quemerina–9 - Google Patents
Derivados cíclicos de quemerina–9Info
- Publication number
- CL2023000412A1 CL2023000412A1 CL2023000412A CL2023000412A CL2023000412A1 CL 2023000412 A1 CL2023000412 A1 CL 2023000412A1 CL 2023000412 A CL2023000412 A CL 2023000412A CL 2023000412 A CL2023000412 A CL 2023000412A CL 2023000412 A1 CL2023000412 A1 CL 2023000412A1
- Authority
- CL
- Chile
- Prior art keywords
- chemerin
- cyclic derivatives
- cyclic
- derivatives
- prophylaxis
- Prior art date
Links
- 125000004122 cyclic group Chemical group 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyclic chemerin-9 derivatives Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a derivados cíclicos de quemerina–9 de fórmula general (I) como se describe y define en el presente documento, métodos para preparar dichos péptidos y el uso de dichos compuestos para el tratamiento o profilaxis de enfermedades, en particular cáncer, diabetes, obesidad y trastornos inflamatorios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20190794 | 2020-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000412A1 true CL2023000412A1 (es) | 2023-08-04 |
Family
ID=72086681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000412A CL2023000412A1 (es) | 2020-08-12 | 2023-02-09 | Derivados cíclicos de quemerina–9 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230303647A1 (es) |
| EP (1) | EP4196143A1 (es) |
| JP (1) | JP2023537111A (es) |
| KR (1) | KR20230048130A (es) |
| CN (1) | CN116390742A (es) |
| AU (1) | AU2021324064A1 (es) |
| BR (1) | BR112023001380A2 (es) |
| CA (1) | CA3191321A1 (es) |
| CL (1) | CL2023000412A1 (es) |
| IL (1) | IL300295A (es) |
| MX (1) | MX2023001723A (es) |
| WO (1) | WO2022034057A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023220676A2 (en) * | 2022-05-12 | 2023-11-16 | Okyo Pharma Limited | Formulation for treating dry eye disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2013117581A1 (en) * | 2012-02-10 | 2013-08-15 | Charite - Universitätsmedizin Berlin | Metabolically stable variants of chemerin 9 |
-
2021
- 2021-08-10 JP JP2023509603A patent/JP2023537111A/ja active Pending
- 2021-08-10 CA CA3191321A patent/CA3191321A1/en active Pending
- 2021-08-10 MX MX2023001723A patent/MX2023001723A/es unknown
- 2021-08-10 IL IL300295A patent/IL300295A/en unknown
- 2021-08-10 WO PCT/EP2021/072236 patent/WO2022034057A1/en unknown
- 2021-08-10 KR KR1020237008225A patent/KR20230048130A/ko unknown
- 2021-08-10 EP EP21762645.6A patent/EP4196143A1/en active Pending
- 2021-08-10 CN CN202180062643.7A patent/CN116390742A/zh active Pending
- 2021-08-10 BR BR112023001380A patent/BR112023001380A2/pt not_active Application Discontinuation
- 2021-08-10 AU AU2021324064A patent/AU2021324064A1/en active Pending
- 2021-08-10 US US18/020,878 patent/US20230303647A1/en active Pending
-
2023
- 2023-02-09 CL CL2023000412A patent/CL2023000412A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230048130A (ko) | 2023-04-10 |
| WO2022034057A1 (en) | 2022-02-17 |
| BR112023001380A2 (pt) | 2023-02-23 |
| US20230303647A1 (en) | 2023-09-28 |
| CA3191321A1 (en) | 2022-02-17 |
| EP4196143A1 (en) | 2023-06-21 |
| IL300295A (en) | 2023-04-01 |
| CN116390742A (zh) | 2023-07-04 |
| AU2021324064A1 (en) | 2023-03-09 |
| JP2023537111A (ja) | 2023-08-30 |
| MX2023001723A (es) | 2023-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125051T1 (el) | Συντηγμενη ενωση αναστολεα jak ιμιδαζο-πιπεριδινης | |
| CY1119170T1 (el) | Ενωση γουανιδινης | |
| CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
| ECSP078060A (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
| MX2020001235A (es) | Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona. | |
| EA201990833A1 (ru) | Соединение пиридина | |
| CY1124243T1 (el) | Αναστολη του ιοντικου διαυλου υποδοχεα παροδικου δυναμικου α1 | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| DOP2009000287A (es) | Oxazolidinonas sustituidas y su uso | |
| CR20140392A (es) | Dihidropirazolonas sustituidas | |
| CR10211A (es) | Compuestos de tiazol y métodos de uso | |
| ECSP088338A (es) | Terapia de combinación de oxazolidinonas sustituidas para la profilaxis y el tratamiento de alteraciones del flujo sanguíneo cerebral | |
| UY29149A1 (es) | Tiazolil-dihidro-indazoles | |
| UY32240A (es) | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. | |
| EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
| EA202091803A1 (ru) | Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat) | |
| ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
| CL2023000412A1 (es) | Derivados cíclicos de quemerina–9 | |
| CY1117706T1 (el) | Παραγωγα οξαζολινης και ισοξαζολινης ως ρυθμιστες crac | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| UY31133A1 (es) | "oxazolidinonas sustituidas y su uso" | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| BR112021019099A2 (pt) | Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
| BR112021011729A2 (pt) | Tubulisinas e conjugados de proteína-tubulisina | |
| CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). |